Nexalin Technology, Inc. (NXL) shares are declining more than 33 percent on Friday morning trade. The shares started to trend down after reaching 1.50 Thursday after the company announced approval for its Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency.
Currently, shares are at $0.91, down 33.81 percent from the previous close of $1.38 on a volume 2,149,253.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.